Fig. 1

JAK inhibition and a therapeutic approach for CRC. Representative image of IHC staining for pSTAT3^tyr705 in a KPN and AKPT mouse tumor (A). Bar chart showing the effect of JAK inhibitors on expression of pSTAT3^tyr705 as measured by ELISA (B). Plot showing the effect of JAK inhibitors in control and in HCT116s with STAT3 knocked down (C). Representative images showing patient derived explants derived from matched normal and tumor colon samples and stained for Ki67via IHC after treatment with vehicle, Ruxolitinib or Tofacitinib (D). Brightfield images showing the effect of vehicle control, Ruxolitinib, Tofacitinib and 5FU on KPN and AKPT organoids after 72 h treatment (E). Representative images of immunofluorescent (IF) staining for Ki67 in an untreated and Ruxolitinib treated KPN mouse organoid (F). Box plot showing the effect of treatment with vehicle control, Ruxolitinib, Tofacitinib and 5FU for 72 h on cell viability of KPN and AKPT organoids (G). Representative images of IF staining for Ki67 and Caspase 8 in an untreated and Ruxolitinib treated PDO line (H). Dot plots showing the effect of treatment with vehicle control, Ruxolitinib, Tofacitinib and 5FU for 72 h on cell viability of 7 PDO lines with error bars represented by standard deviation and drug treatment compared to vehicle control by ANOVA (I). Significance set to *p < 0.05, **p < 0.005, p < 0.0005***